 |
|
Carbamazepine Maintenance Treatment in Outpatient Schizophrenics
William T. Carpenter, Jr, MD;
Rose Kurz, PhD;
Brian Kirkpatrick, MD;
Thomas E. Hanlon, PhD;
Ann T. Summerfelt;
Robert W. Buchanan, MD;
Royce W. Waltrip, MD;
Alan Breier, MD
Arch Gen Psychiatry. 1991;48(1):69-72.
Abstract
• A double-blind crossover trial was used to evaluate Carbamazepine as the sole maintenance treatment of chronic, nonmanic schizophrenic outpatients whose conditions had been stabilized with the use of neuroleptics prior to study. Criteria of treatment effectiveness included the number of patients relapsing and time to relapse over a 95-day neuroleptic-free period during which either carbamazepine or placebo was administered. Relapse was determined by the concordance of psychiatric ratings and independent clinical judgments indicating significant worsening. Results for 27 patients (13 receiving carbamazepine and 14 receiving placebo) involved in the first phase of this treatment comparison were nondifferentiating. Corroborating descriptive findings in the second phase were available for 14 of these patients. There was no evidence supporting the existence of a treatment-relevant subgroup defined by eqisodic dyscontrol phenomena.
Author Affiliations
From the Maryland Psychiatric Research Center, and the Department of Psychiatry, University of Maryland School of Medicine, Baltimore.
Footnotes
Accepted for publication July 20, 1990.
Reprint requests to Maryland Psychiatric Research Center, PO Box 21247, Baltimore, MD 21228 (Dr Carpenter).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large
J Psychopharmacol 2007;21:283-301.
ABSTRACT
Schizophrenia
Kane
NEJM 1996;334:34-42.
FULL TEXT
Schizophrenia
Carpenter and Buchanan
NEJM 1994;330:681-690.
FULL TEXT
|
